Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNB NASDAQ:LNTH NASDAQ:NUVL NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$9.24+0.5%$9.69$4.16▼$11.84$1.37B1.272.05 million shs877,858 shsLNTHLantheus$55.15-0.3%$68.17$47.25▼$118.21$3.75B0.151.20 million shs883,949 shsNUVLNuvalent$79.54+3.4%$78.55$55.53▼$113.51$5.74B1.29534,222 shs720,647 shsTGTXTG Therapeutics$31.71+6.7%$33.13$21.11▼$46.48$5.03B1.882.48 million shs4.39 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO+1.77%-1.82%+0.33%-8.65%-3.26%LNTHLantheus+0.71%-0.66%-21.65%-30.57%-48.07%NUVLNuvalent+0.42%+2.63%-1.11%+0.10%-9.67%TGTXTG Therapeutics+1.36%+5.13%-15.11%-19.71%+26.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89BIO2.5642 of 5 stars3.52.00.00.03.50.80.6LNTHLantheus4.8888 of 5 stars4.33.00.04.23.42.51.9NUVLNuvalent3.2185 of 5 stars4.50.00.00.03.63.30.0TGTXTG Therapeutics4.4178 of 5 stars3.40.00.03.53.62.52.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89BIO 3.00Buy$26.63188.15% UpsideLNTHLantheus 2.67Moderate Buy$91.6066.09% UpsideNUVLNuvalent 3.08Buy$119.3650.07% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2545.85% UpsideCurrent Analyst Ratings BreakdownLatest ETNB, TGTX, NUVL, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025NUVLNuvalentRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$105.008/30/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/25/2025ETNB89BIOBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.008/14/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/8/2025ETNB89BIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.008/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.007/29/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/21/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$115.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89BION/AN/AN/AN/A$3.52 per shareN/ALNTHLantheus$1.52B2.47$7.13 per share7.74$17.16 per share3.21NUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/ATGTXTG Therapeutics$454.07M11.08$0.13 per share244.49$1.74 per share18.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)LNTHLantheus$312.44M$3.7614.678.74N/A17.82%34.06%19.10%11/5/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3785.7031.71N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest ETNB, TGTX, NUVL, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89BION/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89BIO0.0715.1915.19LNTHLantheus0.494.294.07NUVLNuvalentN/A13.5713.57TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89BION/ALNTHLantheus99.06%NUVLNuvalent97.26%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipETNB89BIO2.80%LNTHLantheus2.00%NUVLNuvalent10.20%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89BIO40148.31 million144.16 millionOptionableLNTHLantheus70067.99 million66.63 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableETNB, TGTX, NUVL, and LNTH HeadlinesRecent News About These CompaniesWhy Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?5 hours ago | zacks.comTG Therapeutics completes share repurchase program, authorize new $100M programSeptember 3 at 12:24 PM | msn.comTG Therapeutics Board Authorizes New $100M Share Repurchase ProgramSeptember 3 at 12:24 PM | msn.comTG Therapeutics Completes $100 Million Share Repurchase Program and Authorizes New $100 Million Repurchase InitiativeSeptember 3 at 7:50 AM | quiverquant.comQTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million ProgramSeptember 3 at 7:30 AM | globenewswire.comDriehaus Capital Management LLC Takes $30.55 Million Position in TG Therapeutics, Inc. $TGTXSeptember 1 at 5:36 AM | marketbeat.comRafferty Asset Management LLC Has $7.17 Million Holdings in TG Therapeutics, Inc. $TGTXAugust 30, 2025 | marketbeat.comJump Financial LLC Buys New Shares in TG Therapeutics, Inc. $TGTXAugust 30, 2025 | marketbeat.comTG Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 28, 2025 | globenewswire.comRaymond James Financial Inc. Purchases 205,111 Shares of TG Therapeutics, Inc. $TGTXAugust 27, 2025 | marketbeat.comWellington Management Group LLP Boosts Position in TG Therapeutics, Inc. $TGTXAugust 26, 2025 | marketbeat.comTG Therapeutics, Inc. $TGTX Position Decreased by 1832 Asset Management L.P.August 25, 2025 | marketbeat.comTG Therapeutics, Inc. $TGTX Shares Bought by Algert Global LLCAugust 23, 2025 | marketbeat.comTG Therapeutics, Inc. $TGTX Shares Bought by Russell Investments Group Ltd.August 23, 2025 | marketbeat.comTG Therapeutics: Looking For The Stimulus For A TurnaroundAugust 20, 2025 | seekingalpha.comFox Run Management L.L.C. Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)August 19, 2025 | marketbeat.com746,696 Shares in TG Therapeutics, Inc. $TGTX Bought by Nuveen LLCAugust 19, 2025 | marketbeat.comInvesco Ltd. Raises Position in TG Therapeutics, Inc. $TGTXAugust 19, 2025 | marketbeat.comWealthedge Investment Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)August 17, 2025 | marketbeat.comSector Gamma AS Acquires Shares of 55,000 TG Therapeutics, Inc. (NASDAQ:TGTX)August 17, 2025 | marketbeat.comTG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You ThinkAugust 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETNB, TGTX, NUVL, and LNTH Company Descriptions89BIO NASDAQ:ETNB$9.24 +0.05 (+0.54%) Closing price 04:00 PM EasternExtended Trading$9.24 0.00 (0.00%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Lantheus NASDAQ:LNTH$55.15 -0.14 (-0.25%) Closing price 04:00 PM EasternExtended Trading$55.15 0.00 (0.00%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Nuvalent NASDAQ:NUVL$79.54 +2.64 (+3.43%) Closing price 04:00 PM EasternExtended Trading$79.58 +0.03 (+0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$31.71 +1.98 (+6.66%) Closing price 04:00 PM EasternExtended Trading$31.50 -0.21 (-0.66%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
